Ryvu Therapeutics SA (9Y4) Financial Statements
Ryvu Therapeutics SA Financial Overview
Ryvu Therapeutics SA's market cap is currently $88.76M. The company's EPS TTM is $-3.01; its P/E ratio is -5.64; Ryvu Therapeutics SA has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 62.25M | $ 77.97M | $ 46.86M | $ 38.80M | $ 11.19M |
| Gross Profit | $ -117.03M | $ 58.39M | $ 29.31M | $ 21.40M | $ -2.54M |
| Operating Income | $ -122.15M | $ -122.10M | $ -100.95M | $ -78.42M | $ -103.78M |
| EBITDA | $ -112.71M | $ -96.83M | $ -81.04M | $ -65.21M | $ -65.96M |
| Net Income | $ -101.23M | $ -111.44M | $ -92.11M | $ -83.78M | $ -79.08M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 107.68M | $ 225.40M | $ 233.67M | $ 102.44M | $ 88.23M |
| Total Assets | $ 224.44M | $ 378.78M | $ 403.20M | $ 474.98M | $ 228.81M |
| Total Debt | $ 71.72M | $ 75.51M | $ 906.00K | $ 2.77M | $ 5.07M |
| Net Debt | $ 12.11M | $ -84.56M | $ -57.03M | $ -99.15M | $ -78.17M |
| Total Liabilities | $ 153.69M | $ 234.89M | $ 143.61M | $ 131.59M | $ 59.39M |
| Stockholders' Equity | $ 53.83M | $ 143.88M | $ 259.59M | $ 343.39M | $ 161.30M |
| Cash Flow | |||||
| Free Cash Flow | $ -117.75M | $ -135.38M | $ -88.11M | $ 12.03M | $ -69.85M |
| Operating Cash Flow | $ -110.28M | $ -129.48M | $ -84.55M | $ 21.32M | $ -57.87M |
| Investing Cash Flow | $ 13.35M | $ 137.16M | $ -195.54M | $ 690.00K | $ 8.06M |
| Financing Cash Flow | $ -3.05M | $ 94.21M | $ 240.83M | $ -2.46M | $ -3.17M |
Currency in PLN